MedTrace Logo

Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate

NCT03319914 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2018-11-20

No results posted yet for this study

Summary

This is an 8-week observational follow-up study of patients who participated in the ST-001 CALISTA study (A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial).

Conditions

  • Calciphylaxis

Sponsors & Collaborators

  • Hope Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Craig Sherman, MD · Hope Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-20
Primary Completion
2018-11-09
Completion
2018-11-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03319914 on ClinicalTrials.gov